S100A9 has a protective role in inflammation-induced skin carcinogenesis

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 798-808

  McNeill, Eileen ^a,b   Hogg, Nancy ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

inflammation; MRP 14; neutrophils; S100A9; skin carcinogenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CALGRANULIN A; CALGRANULIN B; KI 67 ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CANCER INCIDENCE; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS; FEMALE; IMMUNOCOMPETENT CELL; KERATINOCYTE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SKIN CARCINOGENESIS; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH;

INFLAMMATION; MRP-14; NEUTROPHILS; S100A9; SKIN CARCINOGENESIS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CALGRANULIN A; CALGRANULIN B; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; INFLAMMATION; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; SKIN NEOPLASMS; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE;

EID: 84902257439     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28725     Document Type: Article

References (50)

1. Marenholz I, Heizmann CW, Fritz G,. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-22.
2. Gebhardt C, Nemeth J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-31.
3. Donato R, Cannon BR, Sorci G, et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
4. Markowitz J, Carson WE, III,. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta 2013; 1835: 100-9.
5. Edgeworth J, Gorman M, Bennett R, et al. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991; 266: 7706-13.
6. +-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes. J Biol Chem 2001; 276: 35818-25.
7. Kerkhoff C, Voss A, Scholzen TE, et al. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 2012; 21: 822-6.
8. Srikrishna G, Panneerselvam K, Westphal V, et al. Two proteins modulating transendothelial migration of leukocytes recognize novel carboxylated glycans on endothelial cells. J Immunol 2001; 166: 4678-88.
9. Robinson MJ, Tessier P, Poulsom R, et al. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002; 277: 3658-65.
10. Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-43.
11. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
12. Hobbs JA, May R, Tanousis K, et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003; 23: 2564-76.
13. Manitz MP, Horst B, Seeliger S, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-43.
14. Schnekenburger J, Schick V, Kruger B, et al. The calcium binding protein S100A9 is essential for pancreatic leukocyte infiltration and induces disruption of cell-cell contacts. J Cell Physiol 2008; 216: 558-67.
15. Croce K, Gao H, Wang Y, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 2009; 120: 427-36.
16. Shimizu K, Libby P, Rocha VZ, et al. Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection. Circulation 2011; 124: 2920-32.
17. Lackmann M, Cornish CJ, Simpson RJ, et al. Purification and structural analysis of a murine chemotactic cytokine (CP-10) with sequence homology to S100 proteins. J Biol Chem 1992; 267: 7499-504.
18. Ryckman C, Vandal K, Rouleau P, et al. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170: 3233-42.
19. Srikrishna G,. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun 2012; 4: 31-40.
20. Ichikawa M, Williams R, Wang L, et al. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9: 133-48.
21. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165-78.
22. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205: 2235-49.
23. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666-75.
24. Ramachandran IR, Martner A, Pisklakova A, et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 2013; 190: 3815-23.
25. Gebhardt C, Breitenbach U, Tuckermann JP, et al. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 2002; 21: 4266-76.
26. Berlin-Rufenach C, Otto F, Mathies M, et al. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med 1999; 189: 1467-78.
27. Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68: 869-77.
28. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.
29. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
30. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68: 855-67.
31. Groves RW, Rauschmayr T, Nakamura K, et al. Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J Clin Invest 1996; 98: 336-44.
32. Hanahan D, Coussens LM,. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
33. Robinson MJ, Hogg N,. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun 2000; 275: 865-70.
34. Li X, Eckard J, Shah R, et al. Interleukin-1α up-regulation in vivo by a potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and control of DMBA-induced inflammatory responses. Cancer Res 2002; 62: 417-23.
35. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993; 101: 701-5.
36. Gebhardt C, Riehl A, Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-85.
37. Leibold JS, Riehl A, Hettinger J, et al. Keratinocyte-specific deletion of the receptor RAGE modulates the kinetics of skin inflammation in vivo. J Invest Dermatol 2013; 133: 2400-6.
38. Riehl A, Nemeth J, Angel P, et al. The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal 2009; 7: 12.
39. Saintigny G, Schmidt R, Shroot B, et al. Differential expression of calgranulin A and B in various epithelial cell lines and reconstructed epidermis. J Invest Dermatol 1992; 99: 639-44.
40. Martinsson H, Yhr M, Enerback C,. Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation. Exp Dermatol 2005; 14: 161-8.
41. Voss A, Bode G, Sopalla C, et al. Expression of S100A8/A9 in HaCaT keratinocytes alters the rate of cell proliferation and differentiation. FEBS Lett 2011; 585: 440-6.
42. Khammanivong A, Wang C, Sorenson BS, et al. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS One 2013; 8: e69395.
43. Nukui T, Ehama R, Sakaguchi M, et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem 2008; 104: 453-64.
44. Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008; 83: 1484-92.
45. Katz AB, Taichman LB,. A partial catalog of proteins secreted by epidermal keratinocytes in culture. J Invest Dermatol 1999; 112: 818-21.
46. Melle C, Ernst G, Schimmel B, et al. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res 2004; 64: 4099-104.
47. Roesch Ely M, Nees M, Karsai S, et al. Transcript and proteome analysis reveals reduced expression of calgranulins in head and neck squamous cell carcinoma. Eur J Cell Biol 2005; 84: 431-44.
48. Fung LF, Lo AK, Yuen PW, et al. Differential gene expression in nasopharyngeal carcinoma cells. Life Sci 2000; 67: 923-36.
49. +-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene 2004; 23: 1291-9.
50. Zhu H, Wu TC, Chen WQ, et al. Roles of galectin-7 and S100A9 in cervical squamous carcinoma: clinicopathological and in vitro evidence. Int J Cancer 2013; 132: 1051-9.